Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL
September 03, 2019 02:00 ET
|
Autolus Therapeutics plc
Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete...
Autolus Therapeutics to Participate in Upcoming Investor Conferences in September
August 28, 2019 16:05 ET
|
Autolus Therapeutics plc
LONDON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8
August 02, 2019 09:06 ET
|
Autolus Therapeutics plc
LONDON, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Participate in Upcoming Investor Conferences in June
May 28, 2019 16:55 ET
|
Autolus Therapeutics plc
LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
May 14, 2019 06:30 ET
|
Autolus Therapeutics plc
LONDON, May 14, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia
April 23, 2019 07:49 ET
|
Autolus Therapeutics plc
LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
Autolus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
April 15, 2019 16:02 ET
|
Autolus Therapeutics plc
LONDON, April 15, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Pricing of Public Offering
April 10, 2019 21:19 ET
|
Autolus Therapeutics plc
LONDON, April 10, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Proposed Public Offering in the United States
April 08, 2019 16:40 ET
|
Autolus Therapeutics plc
LONDON, April 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Host R&D Day on March 26, 2019
March 07, 2019 16:05 ET
|
Autolus Therapeutics plc
Company to highlight next-generation, novel programmed T cell therapies in development for hematological and solid tumor indications Program and webcast to begin at 8:00 am ET LONDON, March 07,...